Financing led by DreamCIS will accelerate and expand development of the company's industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data ...

Platform now available to pharmaceutical research partners; powers collaborations totaling over $200 million SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery ...

Partnership has already generated high-quality, AI-ready data in less than three months MOUNTAIN VIEW, CA / ACCESS Newswire / January 8, 2026 / AbTherx today announced a therapeutic antibody discovery ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...